Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

Data from the DESTINY-Breast06 trial support the positive opinion on trastuzumab deruxtecan as a treatment in HER2-low or HER2-ultralow breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

After treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, switching to camizestrant plus a CDK4/6 inhibitor showed a PFS benefit over remaining on the aromatase inhibitor.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Data from the CheckMate 7FL trial may inform treatment decisions regarding preoperative immunotherapy for patients with breast cancer.

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.